ArticleRheumatology (Oxford, England)2025
How have the clinical, laboratory, treatment features and outcomes in children with lupus nephritis progressed over the last 30 years?
Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Paediatric lupus nephritis: defining remission and the evolving therapeutic landscape.Pediatric nephrology (Berlin, Germany) · 2026Article
- Kidney Biopsy and Prognosis in Lupus Nephritis: Histological Predictors of Renal Outcome-A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Clinical, laboratory, and histopathological characteristics of pediatric lupus nephritis: a retrospective study in a national referral center in Mexico.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesManagement of systemic lupus erythematosus (SLE) through new treatment options has improved lupus nephritis (LN) prognosis. The aim of this study was to compare the changes in the demographic, laboratory, and treatment characteristics, prognosis, and outcomes of paediatric-onset LN patients over 30 years.
methodsWe retrospectively reviewed the medical records of 103 paediatric-onset LN patients. Patients were divided into two subgroups according to the years of LN diagnosis. Group 1 consisted of patients diagnosed with LN between the years of 1993 and 2005, and group 2 consisted of patients diagnosed with LN between the years of 2006 and 2023.
resultsThe mean age at diagnosis of SLE, age at diagnosis of LN, time to LN development, and mean delay time to diagnosis were significantly higher in group 1 (P < 0.001, P < 0.001, P = 0.049, and P = 0.004, respectively). Baseline Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores were higher and anti-phospholipid antibody positivity was more frequent in group 1 (P = 0.040 and P = 0.025, respectively). Azathioprine in the maintenance phase was given more frequently in group 1 (P = 0.016), while rituximab was more frequently used in group 2 (P = 0.042). In both groups, the majority of the patients had proliferative LN (class III and/or class IV) (53.5% in group 1 vs. 68% in group 2). Complete renal remission was significantly more common in group 2 (P = 0.005), while end-stage kidney disease (ESKD) and death were significantly more common in group 1 (P = 0.005 and P = 0.001, respectively). Proteinuria and SLEDAI scores at the first visit were independent risk factors for progression to ESKD (P = 0.037 and P = 0.024).
conclusionOver the years, there have been significant improvements in the diagnosis and management of children with SLE resulting in an earlier diagnosis, lower disease activity at onset, and improved outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.